LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Trial Profile

LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2015

At a glance

  • Drugs Octreotide (Primary)
  • Indications Diarrhoea
  • Focus Therapeutic Use
  • Acronyms LARCID
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 02 Apr 2014 Integrated data from ClinicalTrials.gov.
    • 02 Apr 2014 New trial record
    • 10 Feb 2014 Results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top